Get the Stockscreener App
10.56
3.91%
-0.4511
Zevra Therapeutics Inc stock is traded at $10.56, with a volume of 827.20K.
It is down -3.91% in the last 24 hours and up +36.52% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$11.01
Open:
$10.71
24h Volume:
827.20K
Relative Volume:
0.46
Market Cap:
$593.91M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-8.1852
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-0.66%
1M Performance:
+36.52%
6M Performance:
+53.33%
1Y Performance:
+29.66%
1-Day Range:
$10.40
$10.89
1-Week Range:
$9.93
$11.23
52-Week Range:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
10.58 | 618.05M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.94 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.36 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down Following Insider Selling - MarketBeat
What the charts say about Zevra Therapeutics Inc. today2025 Dividend Review & Weekly Top Performers Watchlists - newser.com
Using economic indicators to assess Zevra Therapeutics Inc. potentialStop Loss & Weekly Top Stock Performers List - newser.com
Should you wait for a breakout in Zevra Therapeutics Inc.Analyst Downgrade & Entry and Exit Point Strategies - newser.com
Will breakout in Zevra Therapeutics Inc. lead to full recoveryProduct Launch & Low Drawdown Momentum Trade Ideas - newser.com
What to do if you’re stuck in Zevra Therapeutics Inc.Market Trend Summary & Reliable Momentum Entry Alerts - newser.com
Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells 19,500 Shares of Stock - MarketBeat
Zevra Therapeutics, Inc. $ZVRA Position Cut by Janney Montgomery Scott LLC - MarketBeat
Zevra Therapeutics CEO Neil McFarlane sells $210k in shares By Investing.com - Investing.com Nigeria
Zevra Therapeutics CEO Neil McFarlane sells $210k in shares - Investing.com India
Can Zevra Therapeutics Inc. (1GDA) stock sustain breakout momentumDip Buying & Stepwise Trade Signal Implementation - newser.com
How moving averages guide Zevra Therapeutics Inc. tradingJuly 2025 Summary & Stock Timing and Entry Methods - newser.com
Will Zevra Therapeutics Inc. (1GDA) stock test record highs in 2025Trade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
Chart overlay techniques for tracking Zevra Therapeutics Inc.July 2025 Setups & Daily Stock Trend Watchlist - newser.com
What moving averages say about Zevra Therapeutics Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Zevra Therapeutics (ZVRA): Evaluating Valuation Following Insider Buying and Sustained Revenue Growth - Yahoo
Zevra Therapeutics gains amid takeover speculation - MSN
Why global investors buy Zevra Therapeutics Inc. (1GDA) stock2025 Key Highlights & AI Enhanced Trading Signals - newser.com
Using RSI to spot recovery in Zevra Therapeutics Inc.Earnings Risk Report & Long-Term Investment Growth Plans - newser.com
What drives Zevra Therapeutics Inc stock priceBearish Engulfing Patterns & Breakout Portfolio Performance - earlytimes.in
What drives Zevra Therapeutics Inc 1GDA stock priceEx-Dividend Date Alerts & Affordable Market Growth - earlytimes.in
The Three-year Returns Have Been Decent for Zevra Therapeutics (NASDAQ:ZVRA) Shareholders Despite Underlying Losses Increasing - 富途牛牛
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
38,000-Share Inducement: Zevra Therapeutics Awards Options to Two New Hires, Vesting Over 4 Years - Stock Titan
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors - FinancialContent
Will Zevra Therapeutics Inc. rebound enough to break evenMarket Weekly Review & Weekly High Conviction Ideas - newser.com
Is Zevra Therapeutics Inc. (1GDA) stock a top dividend aristocrat candidateInflation Watch & Free Risk Controlled Daily Trade Plans - newser.com
Will Zevra Therapeutics Inc. (1GDA) stock benefit from Fed rate cutsCPI Data & Community Consensus Stock Picks - newser.com
Is Zevra Therapeutics Inc. (1GDA) stock a buy for dividend portfoliosJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Visual trend scoring systems applied to Zevra Therapeutics Inc.2025 Major Catalysts & Fast Gain Stock Tips - newser.com
How to use a screener to detect Zevra Therapeutics Inc. breakoutsQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to Hold at Wall Street Zen - Defense World
Will Zevra Therapeutics Inc. (1GDA) stock draw ESG focused funds2025 Winners & Losers & Precise Trade Entry Recommendations - newser.com
Can trapped investors hope for a rebound in Zevra Therapeutics Inc.Trade Volume Report & Weekly Setup with ROI Potential - newser.com
How Zevra Therapeutics Inc. (1GDA) stock trades in high volatilityJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
How Investors May Respond To Zevra Therapeutics (ZVRA) European Review of MIPLYFFA for Rare Disease Expansion - Sahm
How institutional ownership impacts Zevra Therapeutics Inc. stockEarnings Overview Summary & Smart Money Movement Alerts - newser.com
Daily Brief United States: Rocket Lab USA , Northwest Biotherapeutics, Fermi, Occidental Petroleum, Intel Corp, Zevra Therapeutics , UP Fintech, Rogers Corp, Rollins Inc, Lockheed Martin and more - Smartkarma
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):